Tirzepatide is an innovative dual GIP (glucose-dependent insulin-releasing polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist for the treatment of diabetes and obesity. As an active pharmaceutical ingredient (API), Tirzepatide regulates blood sugar and body weight by mimicking the effects of GIP and GLP-1.

In diabetes management, Tirzepatide achieves excellent glycemic control by enhancing insulin secretion and lowering fasting and postprandial blood glucose levels. It also improves insulin sensitivity, reduces insulin resistance, and reduces the risk of diabetic complications.

In the treatment of obesity, Tirzepatide helps patients reduce food intake and achieve weight loss by suppressing appetite and increasing feelings of fullness. Clinical studies show that Tirzepatide exhibits good safety and effectiveness in long-term use.

As a raw material powder, Tirzepatide is widely used in a variety of pharmaceutical preparations. Its unique dual receptor agonism mechanism gives it significant advantages in the field of diabetes and obesity treatment. Research and clinical data support its use as an effective treatment option, giving patients new hope for improved health and quality of life.